These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22726267)

  • 21. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
    Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
    Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
    J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-infiltrating lymphocytes in melanoma.
    Lee S; Margolin K
    Curr Oncol Rep; 2012 Oct; 14(5):468-74. PubMed ID: 22878966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
    Goff SL; Smith FO; Klapper JA; Sherry R; Wunderlich JR; Steinberg SM; White D; Rosenberg SA; Dudley ME; Yang JC
    J Immunother; 2010 Oct; 33(8):840-7. PubMed ID: 20842052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
    Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
    Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.
    Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ
    J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
    Dréno B; Nguyen JM; Khammari A; Pandolfino MC; Tessier MH; Bercegeay S; Cassidanius A; Lemarre P; Billaudel S; Labarrière N; Jotereau F
    Cancer Immunol Immunother; 2002 Nov; 51(10):539-46. PubMed ID: 12384805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
    Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
    J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial.
    Dillman RO; Oldham RK; Barth NM; Cohen RJ; Minor DR; Birch R; Yannelli JR; Maleckar JR; Sferruzza A; Arnold J
    Cancer; 1991 Jul; 68(1):1-8. PubMed ID: 2049729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
    Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
    Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
    Martín-Lluesma S; Svane IM; Dafni U; Vervita K; Karlis D; Dimopoulou G; Tsourti Z; Rohaan MW; Haanen JBAG; Coukos G
    Ann Oncol; 2024 Oct; 35(10):860-872. PubMed ID: 39053767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
    Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
    Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.
    Tran KQ; Zhou J; Durflinger KH; Langhan MM; Shelton TE; Wunderlich JR; Robbins PF; Rosenberg SA; Dudley ME
    J Immunother; 2008 Oct; 31(8):742-51. PubMed ID: 18779745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
    Svane IM; Verdegaal EM
    Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.
    Benlalam H; Vignard V; Khammari A; Bonnin A; Godet Y; Pandolfino MC; Jotereau F; Dreno B; Labarrière N
    Cancer Immunol Immunother; 2007 Apr; 56(4):515-26. PubMed ID: 16874485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy.
    Galore-Haskel G; Greenberg E; Yahav I; Markovits E; Ortenberg R; Shapira-Fromer R; Itzhaki O; Schachter J; Besser MJ; Markel G
    Cancer Immunol Immunother; 2021 Jun; 70(6):1541-1555. PubMed ID: 33201337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
    Yeh S; Karne NK; Kerkar SP; Heller CK; Palmer DC; Johnson LA; Li Z; Bishop RJ; Wong WT; Sherry RM; Yang JC; Dudley ME; Restifo NP; Rosenberg SA; Nussenblatt RB
    Ophthalmology; 2009 May; 116(5):981-989.e1. PubMed ID: 19410956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
    Merrouche Y; Negrier S; Bain C; Combaret V; Mercatello A; Coronel B; Moskovtchenko JF; Tolstoshev P; Moen R; Philip T
    J Clin Oncol; 1995 Feb; 13(2):410-8. PubMed ID: 7844602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
    Ben-Avi R; Farhi R; Ben-Nun A; Gorodner M; Greenberg E; Markel G; Schachter J; Itzhaki O; Besser MJ
    Cancer Immunol Immunother; 2018 Aug; 67(8):1221-1230. PubMed ID: 29845338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.